Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Wei Xu

W Mark Eickhoff

Craig B Ikeda

Chad D Brown

Francis J Flanagan, Jr

Rebecca Nofsinger

Lisa Lupton

Hanmi Xi

Paresh B Patel

Leonardo Resende Allain

Mary Ann Johnson

Melanie Marota

Guy R Humphrey

Neville J Anthony

Yaling Wang

Laura Marie Artino

Amar J Mahajan

Marjorie See Waters

Stephanie Elizabeth Barrett

Maria T Cruanes

Marko Cubrovic

Yongchao Su

Daniel Skomski

John V Lepore

Honggang Zhu

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Treatment of migraine

Pharmaceutical formulations for the treatment of migraine

The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4'-Ethynyl-2-fluoro-2′-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.

Crystalline forms of an NRTTI compound

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein 'R' is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Tablet formulation for CGRP active compounds

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein 'R' is independently H or &#x2014;F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. 

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.

Pharmaceutical composition containing an anti-nucleating agent

A sodium salt of Compound A is disclosed, wherein Compound A is of formula:Compound A is an HIV integrase inhibitor useful for preventing or treating HIV infection, for delaying the onset of AIDS, and for treating AIDS.

Sodium salt of an HIV integrase inhibitor

The tris(hydroxymethyl)aminomethane (&ldquo;TRIS&rdquo;) salt of 3-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-&lsqb;1,8&rsqb;-naphthyridin-2-yl)-nonanoic acid is a potent antagonist of the integrin &agr;v&bgr;3 receptor and is useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salt as well as pharmaceutical compositions containing the salt and methods of using the salt.

Amine salt of an integrin receptor antagonist

The present invention relates to novel crystalline forms of the integrin &agr;v&bgr;3 antagonist 3-&lcub;2-oxo-3-&lsqb;3-(5,6,7,8-tetrahydro-&lsqb;1,8&rsqb;naphthyridin-2-yl)-propyl&rsqb;imidazolidin-1-yl&rcub;-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid.

Crystalline forms of an integrin receptor antagonist

Amine salts of -( -methyl-pyrimidin- -yl)- -( -tetrahydro-&lsqb; &rsqb;-naphthyridin- -yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr; receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are (R)- and (S)-( -methylpyrimidin- -yl)- -( -tetrahydro-&lsqb; &rsqb;naphthyridin- -yl)-nonanoic acid in the form of a zwitterion trihydrate.

Amine salts of an integrin receptor antagonist

Growing community of inventors

North Wales, PA, United States of America

Wei Xu